GlassScriptPhysician profile
Lowell S Davis
NPI 1114907409
$15,729.42
in general payments reported to CMS, 2019-2025
33 companies · $1,796 in 2025
The $1,796 reported for 2025 was more than what 76% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,948 · 2020: $615 · 2021: $2,096 · 2022: $1,716 · 2023: $577 · 2024: $2,982 · 2025: $1,796.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,079 · Travel and Lodging: $1,276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,079.31 |
| Travel and Lodging | $1,275.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertiflex, INC. | $4,858.59 | 2019 | |
| Medtronic, INC. | $2,844.41 | 2021-2024 | Kyphon Express II Kyphopak Tray, Osteocool Rf Ablation System |
| Boston Scientific Corporation | $1,374.55 | 2019-2025 | General - Pain Management, Wavewriter Alpha Prime 16 |
| Nalu Medical, INC. | $1,007.38 | 2021-2024 | Nalu Neurostimulation System |
| Abbott Laboratories | $1,000.99 | 2019-2025 | Proclaim, Eterna |
| Nevro Corp. | $977.08 | 2019-2024 | Senza |
| Vertos Medical, INC. | $550.13 | 2019-2024 | Mild Device Kit |
| Spinal Simplicity, LLC | $543.61 | 2023-2025 | Ha Minuteman G3-R |
| Saluda Medical Americas, INC. | $261.35 | 2023-2025 | Evoke, Evoke Scs |
| Orthofundamentals, LLC | $261.08 | 2025 | Trellis Si Joint Fusion System |
| Scilex Pharmaceuticals INC. | $237.82 | 2019-2023 | Ztlido |
| Globus Medical, INC. | $226.43 | 2025 | Senza |
| Collegium Pharmaceutical, INC. | $207.81 | 2019-2024 | Xtampza |
| Medtronic USA, INC. | $189.30 | 2019-2020 | |
| Si-Bone, INC. | $170.16 | 2019-2024 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Forte Bio-Pharma LLC | $166.58 | 2021-2024 | Prolate, Nalocet |
| Depuy Synthes Sales INC. | $122.15 | 2019-2023 | Monovisc, Orthovisc |
| Electronic Waveform Lab, INC. | $120.93 | 2019-2025 | |
| Stryker Corporation | $89.02 | 2024-2025 | Mild Device Kit, Optablate |
| Medline Industries LP | $87.64 | 2024 | |
| Relievant Medsystems, INC. | $85.81 | 2020-2022 | |
| Orthofix Medical, INC. | $76.99 | 2019 | |
| Zyla Life Sciences, INC. | $58.86 | 2019 | |
| Ibsa Pharma INC. | $54.18 | 2023-2024 | Tirosint, Licart, Tirosint |
| Horizon Therapeutics Plc | $30.62 | 2020 | |
| Vertex Pharmaceuticals Incorporated | $22.50 | 2025 | |
| Shionogi INC | $19.30 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $17.72 | 2019 | |
| Lilly USA, LLC | $15.05 | 2019 | |
| Kaleo, INC. | $14.09 | 2019 | |
| Hikma Pharmaceuticals USA | $13.32 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $12.40 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lowell Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.